Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2023 June Clinical Practice Lorlatinib: a new player in the evolving first-line treatment landscape for patients with ALK-... Read more
2023 June Cancer trials Immune-checkpoint inhibition in the treatment of advanced non-small cell lung cancer: a focus ... Read more
2023 May Cancer trials Video with Prof. Dr. Jeroen Dekervel on the place of durvalumab in the treatment of biliary tr... Read more
(sponsored) 2023 February Clinical Practice Immunotherapy for the treatment of early-stage triple negative breast cancer: a new era in bre... Read more
2022 May ELCC 2022 Savolitinib in the treatment of patients with non-small cell lung cancer and MET exon 14 skipp... Read more
2022 May ASCO GI 2022 Lenvatinib plus transarterial chemoembolisation improves clinical outcomes in patients with ad... Read more
